News Releases

News Releases
Events
Presentations

Year

November 18, 2020

Bioventus Receives Authorization to Proceed Under Investigational New Drug Application for Clinical Trial of Placental Tissue Particulate (PTP-001) for the Treatment of Knee OA

DURHAM, NC – November 18, 2020 – Bioventus , a leader in Solutions For Innovative Healing, received authorization to proceed under its investigational new drug (IND) application from the US Food and Drug Administration (FDA), allowing it to proceed to clinical trials of PTP-001 .

November 16, 2020

Bioventus Appoints Chris Yamamoto Senior Vice President of Business Development and Strategy

DURHAM, NC – November 16, 2020 – Bioventus , a global leader in Innovations For Active Healing, has appointed Chris Yamamoto as Senior Vice President of Business Development and Strategy. Yamamoto brings nearly 20 years of experience in mergers & acquisitions and business development.

November 10, 2020

Bioventus to Provide CVS Caremark with its Portfolio of Preferred Options for Knee Osteoarthritis Patients Seeking Pain Relief

DURHAM, NC – November 10 – Beginning January 1, 2021 Bioventus, a global leader in Innovations For Active Healing, will gain preferred access through the CVS Caremark Formulary, to DUROLANE ® , GELSYN-3 ® and SUPARTZ FX ® , for the treatment of knee osteoarthritis (OA) pain.

September 22, 2020

Bioventus Reaches Milestone with 2 Million DUROLANE® Treatments Worldwide

DURHAM, NC – September 22, 2020 – Bioventus , a global leader in Innovations For Active Healing, is celebrating a milestone and recognizing more than 2 million treatments worldwide with DUROLANE, its single-injection, hyaluronic acid (HA) product used in the treatment of pain associated with

September 2, 2020

Bioventus Reports First Use of its SIGNAFUSE Bioactive Bone Graft in Strip Format

DURHAM, NC – September 2, 2020 – Bioventus is sharing results of the first in-patient use of its new SIGNAFUSE Bioactive Bone Graft strips. Rick Placide, M.D. of VCU Health in Richmond, VA, performed a posterolateral lumbar fusion (PLF) and placed the SIGNAFUSE strips in the posterolateral gutters

August 24, 2020

Bioventus Appoints Katrina Church Chief Compliance Officer

DURHAM, NC – August 24, 2020 – Bioventus , a global leader in orthobiologic solutions, has appointed Katrina Church as its Chief Compliance Officer, effective August 24, 2020. Church brings more than 20 years of experience counseling public and private companies to ensure the highest compliance

August 13, 2020

Hyaluronic Acid Provides Knee OA Pain Relief with Lower Costs, Fewer Adverse Outcomes vs. Corticosteroids or Knee Arthroplasty

DURHAM, NC – August 13, 2020 – Intra-articular hyaluronic acid (IHA) knee osteoarthritis (OA) pain relief treatments had lower total medical care costs vs. patients treated with intra-articular corticosteroids (ICS) or total knee arthroplasty (TKA). This according to a retrospective study,

July 16, 2020

Bioventus Makes $15 Million Equity Investment in CartiHeal with an Agreed Option Structure to Acquire Company Upon Milestone Achievements

KFAR SABA, ISRAEL and DURHAM, NC– July 16, 2020 – CartiHeal , developer of the proprietary Agili™-C implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints, has secured an additional $15 million equity investment from Bioventus , a global leader in orthobiologics.

June 25, 2020

Bioventus Receives FDA Clearance of Strip Format of its SIGNAFUSE Bioactive Bone Graft

DURHAM, NC – June 25, 2020 – Bioventus , a global leader in orthobiologic solutions, is launching its SIGNAFUSE Bioactive Bone Graft in a new strip format. The strips consist of 55% bioglass by weight and have been shown to induce higher levels of osteoblast differentiation compared to other

June 15, 2020

Bioventus Selects Bazis NN as Distributor of DUROLANE in Russia

HOOFDDORP, THE NETHERLANDS – June 15, 2020 – Bioventus , a global leader in orthobiologic solutions, has selected Bazis NN as its authorized distributor for DUROLANE , its single-injection joint-fluid osteoarthritis (OA) treatment. OA involves the breakdown, or degeneration, of cartilage and the

First page
Previous page
…
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Current page 9
Page 10
Page 11
Next page
Last page

Displaying 81 - 90 of 110